Product news from the 11/04/05 News Brief

Share this article:

Novartis announced the FDA's approval of Exjade (deferasirox), a once-daily oral iron chelator designed to treat chronic iron overload due to blood transfusions in adults and children ages two and older.

Roche's Tarceva (erlotinib), has won FDA approval for treatment of advanced pancreatic cancer.

Savient Pharmaceuticals announced the FDA approval of its New Drug Application for Soltamox (tamoxifen oral solution) for the treatment of breast cancer in adjuvant and metastatic settings and to reduce risks of breast cancer in women with ductal carcinoma in situ (DCIS) and reduction of breast cancer incidence in women with high risk of breast cancer. Soltamox is the product of Savient's wholly owned subsidiary, Rosemont Pharmaceuticals Ltd., located in the U.K.

GlaxoSmithKline announced that the FDA has approved Arranon (nelarabine) Injection, a chemotherapy agent for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and Tcell lymphoblastic lymphoma (TLBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions